Cancer CLINICAL TRIALS AND RESEARCH
Renown Institute for Cancer , in collaboration with the National Cancer Institute and the Nevada Cancer Research Foundation , offers over 40 clinical trials for a variety of cancers . Participating in clinical trials and research allows you to receive the most effective therapy available . These treatments investigate promising new drugs , drug combinations , advances in personalized care and new approaches to surgery or radiation therapy that are otherwise unavailable in traditional treatment .
If you are considering a clinical trial , talk to a member of your cancer care team and consult with your doctor . We are here to provide education and guidance in making decisions about your care and treatment . Our specially trained research nurses will help you understand the process and explain what to expect with each visit . We are committed to bringing the highest quality of cancer care to you and your loved ones .
Cancer GENETICS PROGRAM
The Genetic Risk Assessment program works with patients whose personal medical and family history indicates a possible hereditary cancer syndrome . In hereditary cancer , gene mutations can be passed on from generation to generation .
This program has seen more than 2,400 patients since its inception . The majority of patients undergo genetic studies based on comprehensive personal and family history analysis . All results are then reviewed with you and your provider for management decisions . By making genetic testing choices available based on pertinent clinical history , our program can achieve meaningful results and reduce the cost of healthcare .
The program has implemented cancer genetic clinical research protocols , establishing a presence on the regional Institutional Review Board ( IRB ).
Community outreach includes presentations at local tumor boards and lecture series for clinicians , students and administration . Standardizing genetic information into electronic medical records is also underway . Regional implementation of current National Comprehensive Cancer Network ( NCCN ) guidelines is the goal .
R . Nathan Slotnick , MD , PhD Medical Director of Genetics
10